Solid Tumor Clinical Trials
USOR #20186
Tumor-Agnostic Precision Immuno-Oncology and Somatic Targeting Rational for You (TAPISTRY) Phase II Platform Trial (BO41932).
This trial is for patients with solid tumors that are advanced and unresectable or metastatic disease.
Cohort A: ROS1 fusion
- NSCLC excluded
Cohort B: NTRK 1/2/3 fusion
- Prior treatment with NTRK inhibitors Excluded
Cohort C ALK fusion-positive tumors
- NSCLC and neuroblastoma excluded. Prior treatment with a ALK inhibitor excluded